InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has started its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of epidermolysis bullosa (“EB”). According to the company, this is the first time cannabinol has advanced to a Phase 2 clinical trial to be studied as … Continue reading InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Begins Phase 2 Clinical Trial Evaluating CBN in the EB Treatment